Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
- Conditions
- Breast CancerC04.588
- Registration Number
- RBR-26m455f
- Lead Sponsor
- Fundação do ABC - Faculdade de Medicina do ABC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Female: Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial; Age 18 to 49, inclusive; Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines); Is a candidate for endocrine therapy + ovarian suppression; LH > 4 IU/L within 28 days prior to Day 1; Is premenopausal as defined by:E2 > 30 pg/mL; follicle-stimulating hormone (FSH) < 40 IU/L; regular menses (eg, menstrual cycle length of 21 to 35 days). Note: premenopausal status must be determined before neo/adjuvant chemotherapy in patients for which it is planned or prior to Day 1 in patients who did not have prior chemotherapy. If premenopausal status was not determined prior to chemotherapy, E2 and FSH must meet the above criteria when measured 2 weeks or more after the end of the final cycle of chemotherapy. Male: Able to understand the investigational nature of this study and provide written informed consent prior to participation in the trial; Age 18 or older; Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines); Is a candidate for endocrine therapy + GnRH agonist
Female: Body mass index (BMI) < 18.00 kg/m2 or > 35.00 kg/m2. Breastfeeding. Life expectancy < 12 months. Eastern Cooperative Oncology Group (ECOG) performance status =3. Unacceptable hepatic function as determined by any of the following: Alanine aminotransferase (ALT) = 2X upper limit of normal (ULN); Aspartate aminotransferase (AST) = 2X ULN; Bilirubin = 2X ULN; Alkaline phosphatase = 2X ULN; Severe hepatic impairment (Child-Pugh Class C). Unacceptable renal function as determined by any of the following: Creatinine = 3X ULN; Creatinine clearance = 30 mL/minute; Creatinine clearance = 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean. History of significantly abnormal ECG or screening 12-lead ECG demonstrating any of the following: HR > 100 BPM; QRS > 120 msec; QTc > 450 msec; PR > 220 msec. Prior (within 28 days prior to Day 1) and/or concomitant use of medications known to prolong the QT/QTc interval. Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR) inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis. Concomitant use of anticancer mediations other than those specified for use by the protocol. Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer. History of treatment for osteopenia/osteoporosis. Prior (within 6 months prior to Day 1) or current use of drugs known to increase bone mineral density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab) or use of supplements known to increase bone mineral density (ie, calcitonin, fluoride, strontium) within 28 days prior to Day 1. Low trauma fracture(s) occurring within 12 months prior to subject’s first visit (defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull). Conditions that preclude bone mineral density measurement (lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring [not willing to remove] or weight that exceeds the DEXA machine limitation). Any other medical condition or serious illness, presence of a second malignancy under current treatment or follow-up, or the presence of clinically significant findings on the physical exam, laboratory testing, medical history (including conditions that may be associated with low bone mass), that in the opinion of the Investigator may interfere with trial conduct, subject safety, or interpretation of study results. Already receiving and/or previously received GnRH analogs within 1 year before breast cancer diagnosis. Psychiatric, addictive, or other disorders that would preclude study compliance. Use of medications that may impact subject safety and/or affect the PK of the drug and hormonal assessments including but not limited to: Oral or transdermal hormonal therapy within 30 days prior to subject’s first visit; Estrogen, progesterone, or androgens within 30 days prior to subject’s first visit; Hormonal contraceptives within 30 days prior to subject’s first visit; Medications known to result in clinically important decreases in bone mass taken within 6 months prior to subject’s first visit. Known hypersensitivity, idiosyncratic, or allergic reactions to GnRH, GnRH agonist/analogs or to any of the components of the IP. Sexually active with a male partner and not willing to use non-hormonal contraceptive metho
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To obtain ovarian suppression, as verified by LH level quantified by enzyme-linked immunosorbent assay (ELISA) method and defined as = 90% of all subjects with LH levels < 4 IU/L at Week 6
- Secondary Outcome Measures
Name Time Method To determine the percent of all subjects with LH levels < 4 IU/L at Weeks 12, 24, 36, and 48 and overall (maintained from Week 6 to 48), quantified by enzyme-linked immunosorbent assay (ELISA) ;To obtain the percent of all subjects with E2 levels < 20 pg/mL at Week 6, quantified by liquid chromatography-mass spectrometry;To determine the percent of subjects with suppression of E2 overall (from Week 6 to Week 48) and<br>percent with suppression at Weeks 12, 24, 36 and 48, by liquid chromatography-mass spectrometry, defined as: < 20 pg/mL in subjects treated with TOL2506 + tamoxifen; < 2.72 pg/mL in subjects treated with TOL2506 + letrozole, anastrozole, or<br>exemestane;To obtain the percent of all subjects with no menses at Week 6 (ie, no menses after Week 5);To obtain no menses in subjects at Weeks 12, 24, 36, and 48 and overall (from Week 6 to 48)